The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Epaminondas Samantas - One of the best experts on this subject based on the ideXlab platform.
-
xeliri bevacizumab versus folfiri bevacizumab as first Line Treatment in patients with metastatic colorectal cancer a hellenic cooperative oncology group phase iii trial with collateral biomarker analysis
BMC Cancer, 2012Co-Authors: Dimitrios Pectasides, Epaminondas Samantas, George Papaxoinis, Konstantine T Kalogeras, Anastasia G Eleftheraki, Ioannis Xanthakis, Thomas Makatsoris, Ioannis Varthalitis, Pavlos Papakostas, Nikitas NikitasAbstract:Background The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-Line Treatment in patients with metastatic colorectal cancer.
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:Purpose Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. Patients and Methods A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. Results Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard rati...
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:PURPOSE: Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. PATIENTS AND METHODS: A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. RESULTS: Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard ratio [HR], 1.08; 95% CI, 0.92 to 1.27; P = .37). There was no evidence of Treatment difference between the cisplatin and carboplatin arms according to sex, stage, performance status, or age. Median PFS was 5.5 and 5.3 months for cisplatin and carboplatin, respectively (HR, 1.10; 95% CI, 0.94 to 1.29; P = .25). ORR was 67.1% and 66.0%, respectively (relative risk, 0.98; 95% CI, 0.84 to 1.16; P = .83). Toxicity profile was significantly different for each of the arms: hematologic toxicity was higher with carboplatin, and nonhematologic toxicity was higher with cisplatin. CONCLUSION: Our meta-analysis of individual patient data suggests no differences in efficacy between cisplatin and carboplatin in the first-Line Treatment of SCLC, but there are differences in the toxicity profile.
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:Purpose Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. Patients and Methods A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. Results Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard ratio [HR], 1.08; 95% CI, 0.92 to 1.27; P .37). There was no evidence of Treatment difference between the cisplatin and carboplatin arms according to sex, stage, performance status, or age. Median PFS was 5.5 and 5.3 months for cisplatin and carboplatin, respectively (HR, 1.10; 95% CI, 0.94 to 1.29; P .25). ORR was 67.1% and 66.0%, respectively (relative risk, 0.98; 95% CI, 0.84 to 1.16; P .83). Toxicity profile was significantly different for each of the arms: hematologic toxicity was higher with carboplatin, and nonhematologic toxicity was higher with cisplatin.
Massimo Di Maio - One of the best experts on this subject based on the ideXlab platform.
-
Second-Line Treatment options in hepatocellular carcinoma
BioExcel Publishing Ltd, 2019Co-Authors: Donatella Marino, Clizia Zichi, Marco Audisio, Elisa Sperti, Massimo Di MaioAbstract:For many years, sorafenib has been the only approved systemic Treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-Line Treatment have failed to prove any survival benefit. However, in the past few years, several advances have been made especially in pretreated patients; phase III trials of regorafenib, cabozantinib, and ramucirumab in patients with elevated α-fetoprotein have demonstrated efficacy in patients progressing after or intolerant to sorafenib. In addition, early phase I and II trials have shown promising results of immunotherapy alone or in combination with tyrosine-kinase inhibitors or monoclonal antibodies in the same setting of patients. In this review, we will discuss the evidence on second-Line options for HCC, focusing on the latest results that are currently refining the Treatment scenario
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:Purpose Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. Patients and Methods A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. Results Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard rati...
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:PURPOSE: Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. PATIENTS AND METHODS: A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. RESULTS: Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard ratio [HR], 1.08; 95% CI, 0.92 to 1.27; P = .37). There was no evidence of Treatment difference between the cisplatin and carboplatin arms according to sex, stage, performance status, or age. Median PFS was 5.5 and 5.3 months for cisplatin and carboplatin, respectively (HR, 1.10; 95% CI, 0.94 to 1.29; P = .25). ORR was 67.1% and 66.0%, respectively (relative risk, 0.98; 95% CI, 0.84 to 1.16; P = .83). Toxicity profile was significantly different for each of the arms: hematologic toxicity was higher with carboplatin, and nonhematologic toxicity was higher with cisplatin. CONCLUSION: Our meta-analysis of individual patient data suggests no differences in efficacy between cisplatin and carboplatin in the first-Line Treatment of SCLC, but there are differences in the toxicity profile.
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:Purpose Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. Patients and Methods A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. Results Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard ratio [HR], 1.08; 95% CI, 0.92 to 1.27; P .37). There was no evidence of Treatment difference between the cisplatin and carboplatin arms according to sex, stage, performance status, or age. Median PFS was 5.5 and 5.3 months for cisplatin and carboplatin, respectively (HR, 1.10; 95% CI, 0.94 to 1.29; P .25). ORR was 67.1% and 66.0%, respectively (relative risk, 0.98; 95% CI, 0.84 to 1.16; P .83). Toxicity profile was significantly different for each of the arms: hematologic toxicity was higher with carboplatin, and nonhematologic toxicity was higher with cisplatin.
-
meta analysis of single agent chemotherapy compared with combination chemotherapy as second Line Treatment of advanced non small cell lung cancer
Journal of Clinical Oncology, 2009Co-Authors: Massimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, Dora Hatzidaki, Koji Takeda, F M Wachters, V Gebbia, Egbert F Smit, Alessandro Morabito, Ciro GalloAbstract:Purpose Doublet chemotherapy is more effective than single-agent as first-Line Treatment of advanced non–small-cell lung cancer (NSCLC). As second-Line Treatment, several randomized trials have been performed comparing single-agent with doublet chemotherapy, but each trial had an insufficient power to detect potentially relevant differences in survival. Methods We performed meta-analysis of individual patient data from randomized trials, both published and unpublished, comparing single-agent with doublet chemotherapy as second-Line Treatment of advanced NSCLC. Primary end point was overall survival (OS). All statistical analyses were stratified by trial. Results Eight eligible trials were identified. Data of two trials were not available, and data of six trials (847 patients) were collected. Median age was 61 years. Performance status was 0 or 1 in 90%; 80% of patients had received previous platin-based chemotherapy. OS was not significantly different between arms (P = .32). Median OS was 37.3 and 34.7 we...
Johan Vansteenkiste - One of the best experts on this subject based on the ideXlab platform.
-
phase iii randomized open label study of durvalumab medi4736 in combination with tremelimumab or durvalumab alone versus platinum based chemotherapy in first Line Treatment of patients with advanced metastatic nsclc mystic
Journal for ImmunoTherapy of Cancer, 2015Co-Authors: Naiyer A Rizvi, Johan Vansteenkiste, Fabrice Barlesi, Julie R Brahmer, Enriqueta Felip, Patrick M Forde, Marina Chiara Garassino, Sarah B Goldberg, Anthony Jarkowski, Stuart McintoshAbstract:Meeting abstracts Platinum-based doublets are standard of care (SoC) first-Line Treatment for advanced NSCLC, but durable benefit is observed infrequently, with resistance to chemotherapy invariably developing. The blockade of immune checkpoints is a promising novel approach in cancer Treatment.
-
second Line Treatment of advanced non small cell lung cancer
Journal of Thoracic Oncology, 2008Co-Authors: Cesare Gridelli, Andrea Ardizzoni, Fortunato Ciardiello, Nasser H Hanna, John V Heymach, Francesco Perrone, Rafael Rosell, Frances A Shepherd, Nick Thatcher, Johan VansteenkisteAbstract:Abstract After failure of first-Line chemotherapy for advanced non-small cell lung cancer, many patients remain candidates to receive further antitumor Treatment. To guide clinical management of these patients and to suggest priorities for clinical research, an International Panel of Experts met in Naples (Italy) in April 2007. Results and evidence-based conclusions are presented in this article. Single-agent chemotherapy with docetaxel or pemetrexed is the recommended option for unselected patients with performance status 0 to 2 who are candidates for second-Line chemotherapy for advanced non-small cell lung cancer. Docetaxel has demonstrated superiority compared with best supportive care. Pemetrexed has been shown to be noninferior to docetaxel, with a more favorable toxicity profile. Erlotinib is effective in pretreated patients, and can be given second-Line in patients not suitable or intolerant to chemotherapy, and in all patients as third-Line Treatment after failure of second-Line chemotherapy. Gefitinib failed to show superiority to placebo as second- or third-Line Treatment, but it has been shown to be noninferior to docetaxel. In selected patients such as lifetime nonsmokers or those of East-Asian ethnicity, erlotinib, or gefitinib (where licensed) may be considered as second-Line Treatment even if they are fit for chemotherapy. Best supportive care in addition to active Treatment remains important for all patients, but may be the exclusive option for patients unsuitable for more aggressive therapy. Further research is mandatory, to find better Treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents.
Paolo Chiodini - One of the best experts on this subject based on the ideXlab platform.
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:PURPOSE: Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. PATIENTS AND METHODS: A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. RESULTS: Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard ratio [HR], 1.08; 95% CI, 0.92 to 1.27; P = .37). There was no evidence of Treatment difference between the cisplatin and carboplatin arms according to sex, stage, performance status, or age. Median PFS was 5.5 and 5.3 months for cisplatin and carboplatin, respectively (HR, 1.10; 95% CI, 0.94 to 1.29; P = .25). ORR was 67.1% and 66.0%, respectively (relative risk, 0.98; 95% CI, 0.84 to 1.16; P = .83). Toxicity profile was significantly different for each of the arms: hematologic toxicity was higher with carboplatin, and nonhematologic toxicity was higher with cisplatin. CONCLUSION: Our meta-analysis of individual patient data suggests no differences in efficacy between cisplatin and carboplatin in the first-Line Treatment of SCLC, but there are differences in the toxicity profile.
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:Purpose Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. Patients and Methods A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. Results Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard rati...
-
carboplatin or cisplatin based chemotherapy in first Line Treatment of small cell lung cancer the cocis meta analysis of individual patient data
Journal of Clinical Oncology, 2012Co-Authors: A Rossi, Massimo Di Maio, Paolo Chiodini, R M Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Fruh, Wendi Qian, Tomohide Tamura, Epaminondas SamantasAbstract:Purpose Since Treatment efficacy of cisplatin- or carboplatin-based chemotherapy in the first-Line Treatment of small-cell lung cancer (SCLC) remains contentious, a meta-analysis of individual patient data was performed to compare the two Treatments. Patients and Methods A systematic review identified randomized trials comparing cisplatin with carboplatin in the first-Line Treatment of SCLC. Individual patient data were obtained from coordinating centers of all eligible trials. The primary end point was overall survival (OS). All statistical analyses were stratified by trial. Secondary end points were progression-free survival (PFS), objective response rate (ORR), and Treatment toxicity. OS and PFS curves were compared by using the log-rank test. ORR was compared by using the Mantel-Haenszel test. Results Four eligible trials with 663 patients (328 assigned to cisplatin and 335 to carboplatin) were included in the analysis. Median OS was 9.6 months for cisplatin and 9.4 months for carboplatin (hazard ratio [HR], 1.08; 95% CI, 0.92 to 1.27; P .37). There was no evidence of Treatment difference between the cisplatin and carboplatin arms according to sex, stage, performance status, or age. Median PFS was 5.5 and 5.3 months for cisplatin and carboplatin, respectively (HR, 1.10; 95% CI, 0.94 to 1.29; P .25). ORR was 67.1% and 66.0%, respectively (relative risk, 0.98; 95% CI, 0.84 to 1.16; P .83). Toxicity profile was significantly different for each of the arms: hematologic toxicity was higher with carboplatin, and nonhematologic toxicity was higher with cisplatin.
-
meta analysis of single agent chemotherapy compared with combination chemotherapy as second Line Treatment of advanced non small cell lung cancer
Journal of Clinical Oncology, 2009Co-Authors: Massimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, Dora Hatzidaki, Koji Takeda, F M Wachters, V Gebbia, Egbert F Smit, Alessandro Morabito, Ciro GalloAbstract:Purpose Doublet chemotherapy is more effective than single-agent as first-Line Treatment of advanced non–small-cell lung cancer (NSCLC). As second-Line Treatment, several randomized trials have been performed comparing single-agent with doublet chemotherapy, but each trial had an insufficient power to detect potentially relevant differences in survival. Methods We performed meta-analysis of individual patient data from randomized trials, both published and unpublished, comparing single-agent with doublet chemotherapy as second-Line Treatment of advanced NSCLC. Primary end point was overall survival (OS). All statistical analyses were stratified by trial. Results Eight eligible trials were identified. Data of two trials were not available, and data of six trials (847 patients) were collected. Median age was 61 years. Performance status was 0 or 1 in 90%; 80% of patients had received previous platin-based chemotherapy. OS was not significantly different between arms (P = .32). Median OS was 37.3 and 34.7 we...
John D Hainsworth - One of the best experts on this subject based on the ideXlab platform.
-
rituximab with short duration chemotherapy followed by 90y ibritumomab tiuxetan as first Line Treatment for patients with follicular lymphoma update of a minnie pearl cancer research network phase ii trial
Journal of Clinical Oncology, 2005Co-Authors: Dianna Shipley, F A Greco, David R Spigel, D Edwards, M Mayfield, K Yost, J P Allerton, John D HainsworthAbstract:6577 Background: First-Line Treatment with chemotherapy/rituximab combinations improves complete remission (CR) rates and lengthens remission duration in patients with follicular NHL. We previously...
-
phase ii trial of rituximab and short duration chemotherapy followed by 90y ibritumomab tiuxetan as first Line Treatment for patients with follicular lymphoma a minnie pearl cancer research network phase ii trial
Journal of Clinical Oncology, 2004Co-Authors: Dianna Shipley, F A Greco, David R Spigel, D L Carrell, C Dannaher, John D HainsworthAbstract:6519 Background: First-Line Treatment with combination chemotherapy + rituximab improves molecular complete remission (CR) rates and lengthens remission duration in patients (pts) with follicular N...
